In the WHAT HEALTH !? newsletter, we highlight the current news in digital health. Find the titles that have made the buzz, the latest trends and innovations as well as the latest news in the field.
Drug development, from identifying a therapeutic target to arriving on the market, takes ten to fifteen years and costs on average between 1 and 2 billion dollars.
Iktos aims to revolutionise the field by using an algorithm to identify new molecules that can become drug candidates and considerably speed up the process while increasing the chances of success in reaching the clinical stage.
This approach has already been validated by Iktos through more than 50 academic and industrial collaborations, with multiple pharmaceutical and biotechnology companies such as Janssen, Merck, Pfizer, Servier, Ono and Teijin among others.
The Lausanne-based laboratory Debiopharm, with its Debiopharm Innovation Fund branch, has just announced with M Ventures, the investment fund of the German laboratory Merck, and Omnes Capital a co-investment of 15.5 million euros in the French start-up Iktos, thus becoming co-shareholders of the company.
Iktos is not the only start-up on which the Vaud-based company is betting. Over the last six years, it has invested CHF 100 million in projects related to digital health and digital technologies for pharmaceutical research and development.
Find out more in the press release or read LeTemps article hereafter.
>> Find all the latest news in the columns of your weekly.
>> Subscribe HERE
See you next Thursday!
Your Swiss Digital Health team